GTC
SLNO

Ghost Tree Capital’s Soleno Therapeutics SLNO Stock Holding History

Ghost Tree Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$7.57M Sell
150,000
-150,000
-50% -$7.18M 2.29% 17
2024
Q2 		$12.2M Buy
300,000
+100,000
+50% +$4.24M 3.83% 5
2024
Q1 		$8.56M Buy
200,000
+87,615
+78% +$3.96M 2.37% 12
2023
Q4 		$4.52M Buy
+112,385
New +$3.2M 1.48% 21

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ghost Tree Capital's SLNO Position: Q3 2024 in Review

Ghost Tree Capital reduced its Soleno Therapeutics (SLNO) stake by 50% in Q3 2024, selling an estimated $7.18M and leaving 150,000 shares worth $7.57M. The position accounts for 2.29% of the portfolio, ranked #17.

Ghost Tree Capital first reported a position in SLNO in Q4 2023 and has held it in 4 quarters since. The position peaked at $12.2M in Q2 2024. 142 funds tracked by Wall St. Rank hold SLNO as of Q3 2024.

  • Ghost Tree Capital held 150,000 shares of Soleno Therapeutics worth $7.57M as of Q3 2024.
  • Ghost Tree Capital sold 150,000 Soleno Therapeutics shares in Q3 2024, an estimated $7.18M.
  • Soleno Therapeutics made up 2.29% of Ghost Tree Capital's portfolio in Q3 2024, its #17 holding.
  • Ghost Tree Capital first reported a position in Soleno Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Ghost Tree Capital's Soleno Therapeutics position peaked at $12.2M in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.